Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A... see more

Recent & Breaking News (NYSEAM:ATNM)

Actinium Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

GlobeNewswire September 27, 2016

Actinium Pharmaceuticals to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant

GlobeNewswire September 26, 2016

Actinium Pharmaceuticals to Host Webinar to Provide Update on Actimab-A Phase 2 Clinical Trial

GlobeNewswire September 21, 2016

Actinium Pharmaceuticals Selects Vector Oncology as its Clinical Research Organization for Actimab-A Phase 2 Trial

GlobeNewswire September 20, 2016

Actinium Pharmaceuticals to Present at Ladenburg Thalmann 2nd Annual Healthcare Conference

GlobeNewswire September 19, 2016

Actinium Pharmaceuticals Presenting at Rodman & Renshaw 18th Annual Global Investment Conference

GlobeNewswire September 13, 2016

Actinium Pharmaceuticals Presenting at the BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference

GlobeNewswire September 9, 2016

Actinium to Present at BIO International Convention and Provide Updates on Actimab-A and Iomab-B Programs

MarketWire Canada May 10, 2016

Actinium Announces Presentation at Joseph Gunnar Pioneers 2016 Conference

MarketWire Canada May 5, 2016

Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B

Marketwired April 25, 2016

UPDATE - Actinium Announces Selection of Zevacor Pharma, Inc. for Clinical Production and Supply of Iomab-B for Pivotal Phase 3 SIERRA Trial

Marketwired April 12, 2016

Actinium Announces Selection of Zevacor Pharma, Inc. for Clinical Production and Supply of Lomab-B for Pivotal Phase 3 SIERRA Trial

Marketwired April 12, 2016

Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B

Marketwired April 6, 2016

Actinium Further Strengthens Clinical Development Team With Hiring of Director of Clinical Operations

Marketwired March 31, 2016

Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

Marketwired March 30, 2016

Actinium to Present at Sidoti Spring 2016 Emerging Growth Convention

Marketwired March 24, 2016

Meet the Biotech Company About to Turn the 120-Year-Old Cancer Radiation Industry on Its Head

Accesswire March 18, 2016

Actinium Pharmaceuticals to Present at the 28th Annual ROTH Conference

Marketwired March 15, 2016

Actinium Pharmaceuticals Files Annual Report and Provides Investor Update

Marketwired March 14, 2016

Actinium Pharmaceuticals Initiates Pursuit of EU Orphan Designation for Iomab-B

Marketwired March 11, 2016